Anastasia S Lambrou, John T Redd, Miles A Stewart, Kaitlin Rainwater-Lovett, Jonathan K Thornhill, Lynn Hayes, Gina Smith, George M Thorp, Christian Tomaszewski, Adolphe Edward, Natalia Elías Calles, Mark Amox, Steven Merta, Tiffany Pfundt, Victoria Callahan, Adam Tewell, Helga Scharf-Bell, Samuel Imbriale, Jeffrey D Freeman, Michael Anderson, Robert P Kadlec
Monoclonal antibody therapeutics to treat COVID-19 have been authorized by the U.S. Food and Drug Administration under Emergency Use Authorization (EUA). Many barriers exist when deploying a novel therapeutic during an ongoing pandemic, and it is critical to assess the needs of incorporating monoclonal antibody infusions into pandemic response activities. We examined the monoclonal antibody infusion site process during the COVID-19 pandemic and conducted a descriptive analysis using data from three sites at medical centers in the U...
January 14, 2022: Disaster Medicine and Public Health Preparedness